Vanguard Personalized Indexing Management LLC Invests $358,000 in Insmed Incorporated (NASDAQ:INSM)

Vanguard Personalized Indexing Management LLC bought a new position in Insmed Incorporated (NASDAQ:INSM) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 5,345 shares of the biopharmaceutical company’s stock, valued at approximately $358,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Capital International Investors purchased a new position in Insmed in the first quarter valued at approximately $43,973,000. Clearbridge Investments LLC purchased a new position in Insmed in the first quarter valued at approximately $25,242,000. Vestal Point Capital LP bought a new stake in Insmed during the 4th quarter valued at $27,891,000. Fiera Capital Corp bought a new stake in Insmed during the 2nd quarter valued at $40,570,000. Finally, Kingdon Capital Management L.L.C. bought a new stake in Insmed during the 4th quarter valued at $12,551,000.

Insider Activity

In other Insmed news, insider Michael Alexander Smith sold 27,871 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $74.35, for a total value of $2,072,208.85. Following the completion of the sale, the insider now directly owns 67,856 shares in the company, valued at $5,045,093.60. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Insmed news, insider Michael Alexander Smith sold 27,871 shares of the firm’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $74.35, for a total value of $2,072,208.85. Following the completion of the transaction, the insider now owns 67,856 shares of the company’s stock, valued at $5,045,093.60. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the transaction, the insider now directly owns 100,100 shares of the company’s stock, valued at approximately $7,157,150. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 78,882 shares of company stock worth $5,765,446. Corporate insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on INSM. Guggenheim boosted their target price on shares of Insmed from $70.00 to $95.00 and gave the company a “buy” rating in a report on Tuesday, July 9th. HC Wainwright reissued a “buy” rating and set a $90.00 target price on shares of Insmed in a report on Thursday, August 29th. Truist Financial lowered their target price on shares of Insmed from $88.00 to $85.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Evercore ISI boosted their target price on shares of Insmed from $42.00 to $75.00 and gave the company an “outperform” rating in a report on Friday, June 21st. Finally, Mizuho boosted their target price on shares of Insmed from $36.00 to $82.00 and gave the company a “buy” rating in a report on Friday, June 7th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and an average target price of $81.40.

Insmed Stock Performance

Insmed stock opened at $72.48 on Friday. The company has a debt-to-equity ratio of 25.05, a current ratio of 2.71 and a quick ratio of 2.53. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $80.53. The firm has a market capitalization of $10.77 billion, a P/E ratio of -13.86 and a beta of 1.11. The company’s 50-day moving average is $74.29 and its 200 day moving average is $53.43.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.72). The company had revenue of $90.34 million for the quarter, compared to the consensus estimate of $87.95 million. Insmed’s revenue for the quarter was up 17.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.78) earnings per share. Research analysts forecast that Insmed Incorporated will post -5.42 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.